Since KCC2 seems to play a strong role in neural hyperactivity after hearing loss, KCC2 enhancer may represent a promising pharmacotherapeutic target for treating tinnitus and/or hyperacusis. The gene discussed is SLC12A5; the disease is hearing loss disorder.